{"id":146745,"date":"2025-07-10T11:53:34","date_gmt":"2025-07-10T09:53:34","guid":{"rendered":"https:\/\/www.startupbusiness.it\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/"},"modified":"2025-07-10T12:12:00","modified_gmt":"2025-07-10T10:12:00","slug":"angelini-ventures-leads-nuclidiums-e84-million-funding-round","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/","title":{"rendered":"Angelini Ventures leads Nuclidium’s \u20ac84 million funding round"},"content":{"rendered":"\n

Angelini Ventures invests in the development of radiopharmaceuticals and copper-based therapies for the treatment of various oncological diseases. The venture capital fund, which is part of Angelini Industries, co-led an \u20ac84 million Series B financing round in Nuclidium. <\/strong>, a clinical-stage radiopharmaceutical company developing a theranostic platform using copper isotopes (Cu-61 and Cu-67) for oncology applications. <\/p>\n\n

The investment, led by Angelini Ventures, Kurma Growth Opportunities Fund, Wellington Partners and Neva, also includes participation from Deep Tech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.Bank and Highlight Capital, in addition to existing investors. <\/p>\n\n

The investment is aimed at supporting the clinical development of the copper isotope therapeutic pipeline, in particular Nuclidium’s copper-61 and copper-67 in various oncological indications. At the same time, the company aims to expand its production and therapeutic capacity through a global network. <\/p>\n\n

Nuclidium’s innovative platform combines molecules that specifically recognise tumours with two special forms of copper: one, called Cu-61, is used to obtain more accurate diagnostic images, while the other, Cu-67, is used to treat tumours. <\/p>\n\n

Thanks to this combination, Nuclidium’s technology aims to overcome some of the limitations of current therapies, such as suboptimal efficacy and difficulties associated with the production of radiopharmaceuticals. <\/p>\n\n

Early results from clinical trials show that the imaging system developed by Nuclidium is better at detecting tumour lesions than currently available tools, providing clearer and more detailed images. The initial data, recently presented by Gary Ulaner at the SNMMI 2025 annual conference, also indicate that the diagnostic product has a good safety profile and could offer superior performance compared to the imaging techniques used today in PET. <\/p>\n\n

Furthermore, initial data on the therapeutic use of the two main compounds are promising: they show a strong ability to concentrate treatment in tumour areas, particularly in metastatic prostate cancer, neuroendocrine tumours and breast cancer. With its products, Nuclidium promises significant potential in both the diagnosis and treatment of tumours, with the prospect of extending access to targeted therapies to a wider population of patients, including in oncology areas where current options are limited. <\/p>\n\n

“Nuclidium is entering the next clinical phases with its main compounds for the diagnosis and treatment of metastatic prostate cancer, neuroendocrine tumours and breast cancer,” says Leila Jaafar, PhD, CEO and co-founder of Nuclidium, in a statement. <\/strong>“Our copper-based radiotheranostics have been developed for use in healthcare delivery and waste management without being critical elements in hospital workflows, thus making this type of therapy more accessible globally. Our innovative, next-generation copper isotope platform also allows us to rapidly develop new targets for a wider range of cancers, particularly those of great relevance to women’s health.” <\/p>\n\n

Thanks to this funding, Nuclidium will continue to expand its global production and manufacturing network for diagnostics and therapeutics, grow its international team, and strengthen strategic collaborations with hospitals and academic centres, initially focusing on Europe and North America. <\/p>\n\n

With the closing of the financing round, Regina Hodits, managing director of Angelini Ventures, joins the Nuclidium Board of Directors, alongside Daniel Parera, partner at Kurma Partners, and Liliana Nordbakk, life science partner at NEVA. <\/p>\n\n

\u201cWe are delighted to have co-led this round of financing in Nuclidium alongside other high-profile European investors. At Angelini Ventures, we continue to identify and support companies that pursue scientifically differentiated opportunities with a clear path to addressing unmet medical needs,” said Regina Hodits, managing director of Angelini Ventures (pictured). “We look for dynamic founders and contexts where our investment, combined with active involvement, can help fully realise therapeutic potential.”<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.<\/p>\n","protected":false},"author":125,"featured_media":146737,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[1743,2236,1143,1407,1136],"companies":[2784],"journalist":[1518],"class_list":["post-146745","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-corporate-venture-en","tag-europa-en","tag-investments","tag-life-sciences","tag-startup-en-2","companies-nuclidium-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","width":150,"height":117,"crop":false,"srcset":false,"alt":"cure oncologiche"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","width":1024,"height":801,"crop":false,"srcset":false,"alt":"cure oncologiche"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","width":1128,"height":882,"crop":false,"srcset":false,"alt":"cure oncologiche"}},"acf":[],"yoast_head":"\nAngelini Ventures leads Nuclidium's \u20ac84 million funding round<\/title>\n<meta name=\"description\" content=\"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angelini Ventures leads Nuclidium's \u20ac84 million funding round\" \/>\n<meta property=\"og:description\" content=\"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T09:53:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T10:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1128\" \/>\n\t<meta property=\"og:image:height\" content=\"882\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Angelini Ventures leads Nuclidium’s \u20ac84 million funding round\",\"datePublished\":\"2025-07-10T09:53:34+00:00\",\"dateModified\":\"2025-07-10T10:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/\"},\"wordCount\":591,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/regina-angelini.webp\",\"keywords\":[\"corporate venture\",\"Europa\",\"investments\",\"Life Sciences\",\"startup\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/\",\"name\":\"Angelini Ventures leads Nuclidium's \u20ac84 million funding round\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/regina-angelini.webp\",\"datePublished\":\"2025-07-10T09:53:34+00:00\",\"dateModified\":\"2025-07-10T10:12:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\\\/146745\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/regina-angelini.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/regina-angelini.webp\",\"width\":1128,\"height\":882,\"caption\":\"cure oncologiche\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Angelini Ventures leads Nuclidium's \u20ac84 million funding round","description":"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/","og_locale":"en_US","og_type":"article","og_title":"Angelini Ventures leads Nuclidium's \u20ac84 million funding round","og_description":"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.","og_url":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/","og_site_name":"Startupbusiness.it","article_published_time":"2025-07-10T09:53:34+00:00","article_modified_time":"2025-07-10T10:12:00+00:00","og_image":[{"width":1128,"height":882,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Angelini Ventures leads Nuclidium’s \u20ac84 million funding round","datePublished":"2025-07-10T09:53:34+00:00","dateModified":"2025-07-10T10:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/"},"wordCount":591,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","keywords":["corporate venture","Europa","investments","Life Sciences","startup"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/","url":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/","name":"Angelini Ventures leads Nuclidium's \u20ac84 million funding round","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","datePublished":"2025-07-10T09:53:34+00:00","dateModified":"2025-07-10T10:12:00+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"The Swiss start-up is engaged in the development of copper-based radiopharmaceuticals for the treatment of cancer.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-leads-nuclidiums-e84-million-funding-round\/146745\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/07\/regina-angelini.webp","width":1128,"height":882,"caption":"cure oncologiche"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/146745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=146745"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/146745\/revisions"}],"predecessor-version":[{"id":146746,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/146745\/revisions\/146746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/146737"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=146745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=146745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=146745"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=146745"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=146745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}